Edgar Filing: Khosrovi Behzad - Form 4/A

Khosrovi Behza	ad									
Form 4/A										
November 17, 2	2010									
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION									OMB APPROVAL	
Washington, D.C. 20549								N OMB Number:	3235-0287	
Check this box if no longer							Expires:	January 31, 2005		
subject to STATEMENT OF CHANG Section 16. Form 4 or					GES IN BENEFICIAL OWNERSHIP OF SECURITIES				average urs per . 0.5	
Form 5 obligations may continu <i>See</i> Instructi 1(b).	e. Section 17(a) of the l	Public U	Jtility Hol	ding Co		nge Act of 1934, of 1935 or Section 940	on		
(Print or Type Resp	ponses)									
1. Name and Address of Reporting Person <u>*</u> Khosrovi Behzad			2. Issuer Name and Ticker or Trading Symbol NovaBay Pharmaceuticals, Inc.				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
			[NBY]				(Cne	eck all applicabl	e)	
(Last)	(First) (I	Middle)	3. Date of	of Earliest T	ransaction		Director		% Owner	
5980 HORTON STREET, SUITE 550			(Month/Day/Year) 11/15/2010				XOfficer (give titleOther (specify below) below) SVP Product Development & CAO			
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year) 11/15/2010				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
EMERYVILL	E, CA 94608						Person	More than One K	eporting	
(City)	(State)	(Zip)	Tal	ole I - Non-J	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	Transaction Date onth/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3,	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report	on a separate line	e for each cl	ass of sec	urities bene	ficially ow	ned directly	or indirectly.			
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.						n are not rm	SEC 1474 (9-02)		
	Tab					posed of, or convertible	Beneficially Owned securities)	1		

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

Edgar Filing: Khosrovi Behzad - Form 4/A



Signatures

/s/ Theresa Granados, Attorney-in-Fact for Behzad Khosrovi	11/17/2010	
<u>**Signature of Reporting Person</u>	Date	

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Original Form 4 filed on November 15, 2010. This amendment is filed to correct the exercise price from \$1.85 to \$1.89 per share.
- (2) Original Form 4 filed on November 15, 2010. This amendment is filed to correct the grant date from November 12, 2010 to November 15, 2010, the date the last signature to the Board Written Consent granting the options was received by the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.